Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13834710 | 0.81 | ERCC5 (0.33) | ADORA2BALDH1A1ERCC5FEN1 | |
| SCHEMBL20014569 | 0.79 | ADORA2B (0.37) | ADORA2BTP53MAPK1USP2ALDH1A1 | |
| SCHEMBL9972907 | 0.78 | ERCC5 (0.32) | ADORA2BALDH1A1ERCC5FEN1 | |
| SCHEMBL9972904 | 0.78 | ALDH1A1 (0.39) | ADORA2BALDH1A1TRPC5 | |
| SCHEMBL9972877 | 0.78 | KMT2A (0.33) | ADORA2BMAPK1ALDH1A1ERCC5FEN1 | |
| SCHEMBL13834835 | 0.74 | TRPA1 (0.38) | ADORA2BTP53ALDH1A1LMNA | |
| SCHEMBL13834829 | 0.73 | TRPA1 (0.46) | ADORA2BALDH1A1LMNATRPC5ERCC5 | |
| SCHEMBL13835019 | 0.73 | TRPA1 (0.37) | ADORA2BUSP2ALDH1A1 | |
| SCHEMBL13175034 | 0.72 | TRPA1 (0.45) | ALDH1A1HTTALOX15TRPC5MAPT | |
| SCHEMBL14181375 | 0.69 | MAPK1 (0.43) | ADORA2BMAPK1USP2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346822-B2 | Thienopyrimidine compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-24 | — | — | US | disclosed |
| EP-2655377-B1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS | GLENMARK PHARMACEUTICALS SA (CH) | 2016-03-30 | — | — | EP | disclosed |
| US-9073955-B2 | 2-amino-4-arylthiazole compounds as TRPA1 antagonists | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-8889862-B2 | 2-amino-4-arylthiazole compounds as TRPA1 antagonists | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2014-11-18 | — | — | US | disclosed |
| US-20140221381-A1 | THIENOPYRIMIDINE COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-07 | — | — | US | disclosed |
| US-8735401-B2 | Thienopyrimidine compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-27 | — | — | US | disclosed |
| US-20140051667-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2014-02-20 | — | — | US | disclosed |
| US-20140045865-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20120157411-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPAI ANTAGONISTS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2012-06-21 | — | — | US | disclosed |
| US-20120071486-A1 | THIENOPYRIMIDINE COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| US-8058280-B2 | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071486-A1 | THIENOPYRIMIDINE COMPOUNDS AND USE THEREOF | GNRHR, KISS1R, NR5A1 | ADORA2B 820/4885TP53 1768/4885MAPK1 2016/4885 |
| US-20120157411-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPAI ANTAGONISTS | TRPA1, TRPV1, TRPV2 | ADORA2B 187/4885TP53 2623/4885MAPK1 2168/4885 |
| US-20140045865-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS | TRPA1, TRPV1, TRPV2 | ADORA2B 140/4885TP53 3238/4885MAPK1 1705/4885 |
| US-20140051667-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS | TRPA1, TRPV1, TRPV2 | ADORA2B 140/4885TP53 3238/4885MAPK1 1705/4885 |
| US-20140221381-A1 | THIENOPYRIMIDINE COMPOUNDS AND USE THEREOF | GNRHR, KISS1R, NR5A1 | ADORA2B 820/4885TP53 1768/4885MAPK1 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.